CURRICULUM VITAE

PERSONAL DATA

Name: Haneen Shalabi, DO

Office Number: (301) 451-7025

Email Address: haneen.shalabi@nih.gov

EDUCATION AND TRAINING

July 2016- Present	Clinical Fellow- Advanced Studies Program in Pediatric Oncology Cellular Therapy in Hematologic Malignancies National Institutes of Health, NCI, POB, Bethesda, MD
July 2013- June 2016	Pediatric Hematology/Oncology Fellowship Children's National Medical Center, Washington, DC
July 2010- June 2013	Pediatric Residency Loyola University, Maywood, IL
August 2006- June 2010	Doctor of Osteopathic Medicine Chicago College of Osteopathic Medicine, Chicago, IL
August 2002- May 2006	Bachelor of Science in Psychology University of Illinois, Urbana-Champaign, Illinois

LICENSURE AND BOARD CERTIFICATION

2017-Present	Certified, American Board of Pediatrics, Hematology-Oncology
2017-Present	Certified, Conscious Sedation
2014-2015	Certified, Introduction to the Principles and Practice of Clinical Research - NIH
2013-Present	Certified, American Board of Pediatrics
2013-Present	Physician License, Medical Board of District of Columbia
2010-Present	Certified, Pediatric Advanced Life Support (PALS)

RESEARCH EXPERIENCE

2016-Present	Associate Investigator; Pediatric Oncology Branch, NIH Bethesda, MD PI Terry J. Fry, MD: Lead Associate Investigator: Nirali N. Shah, MD Phase I dose escalation study of anti-CD22 chimeric antigen receptor T cells in pediatric and young adults with recurrent or refractory CD22-expressing B cell malignancies
2015-Present	Associate Investigator; Pediatric Oncology Branch, NIH Bethesda, MD PI: Nirali N. Shah, MD Lead Associate Investigator: Terry J. Fry, MD

	Phase I dose escalation study of CD19/CD22 chimeric antigen receptor T cells in children and young adults with recurrent or refractory CD19/CD22-expressing B cell malignancies
2014-2016	Research Fellow, Pediatric Oncology Branch, NIH/NCI Bethesda, MD PI: Terry J. Fry, MD Area of interest: Targeted cellular therapy for novel treatment approaches in high-risk pediatric acute lymphoblastic leukemia. Basic laboratory research project with early thymic precursor cell ALL xenograft models.
2007	Research Assistant, Department of Ophthalmology, University of Illinois Chicago, IL PI: Dimitri Azar, MD, MBA Project: VEG-F and its effects on lymphangiogenesis in the cornea

INTERNSHIP EXPERIENCE

2005	Child Life Summer Intern, Department of Bone Marrow Transplant, St Jude Children's Research Hospital, Memphis, TN Administrative duties: creating volunteer schedules, organized play therapy activities, and helped in the revision and completion of the ABC's of cancer project.

PUBLICATIONS

Shalabi H, Angiolillo A, Fry TJ. Beyond CD19: opportunities for future development of targeted immunotherapy in pediatric relapsed-refractory acute leukemia. *Front. Pediatr.* 2015; 3:1-12. PMID: 26484338

Shalabi H, Angiolillo A, Vezina G, et al. Prolonged completed response in a pediatric patient with primary peripheral t-cell lymphoma of the central nervous system. *Pediatr Hematol Oncol.* Epub 2015; PMID: 26384083

Shalabi H, Khuu H, Fry TJ, Shah NN. (2017) Cell-based Therapies: A New Frontier of Personalized Medicine. In Novel Designs of Early Phase Trials for Cancer Therapeutics. (*In Press)*

Fry TJ, Shah NN, Orentas RJ, … **Shalabi H,** et al. CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL. *Nat Med.* 2017; PMID: 29155426

Shalabi H, Kraft Ira, Wang HW, et al. Sequential Loss of Tumor Surface Antigens Following Targeted Treatment with Chimeric Antigen Receptor Therapies in Diffuse Large B-cell Lymphoma. (*In Preparation)*

Shalabi H, Wolters PL, Martin S, et al. Systematic Evaluation of Neurotoxicity in Children and Young Adults Undergoing CD22 Chimeric Antigen Receptor-T Cell Therapy. (*In preparation)*

NATIONAL PRESENTATIONS

Shalabi H, Angiolillo A, Vezina G, Rubenstein JL, Pittaluga S, Raffeld M, Marcus L. Prolonged complete response in a pediatric patient with primary peripheral t-cell lymphoma of the central nervous system. Poster presented at the American Society of Pediatric Hematology/Oncology, Phoenix, AZ 2015

Shalabi H, Turner J, Doros L, Guerrerra M, Rood B, Rossi C, Schore R. A Novel PMS2 Gene Mutation Leading to Constitutional Mismatch Repair Deficiency in a Patient with 3 Distinct Oncologic Diagnoses. Poster presented at the American Society of Pediatric Hematology/Oncology Chicago, IL 2014

Shalabi H, Katsma A, Dugas L, Sarvida ME. Does mainstreaming oncology patients into general pediatric clinics increase rates of febrile neutropenia hospitalizations? Poster presented at the American Society of Pediatric Hematology/Oncology Chicago, IL 2014

Shalabi H, Wolters PL, Marti S, et al. A Prospective Evaluation of Neurocognitive Function and Neurologic Symptoms in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) Undergoing anti-CD22 Chimeric Antigen Receptor Therapy. Poster presented at the American Society of Hematology Meeting San Diego, CA 2016

Shalabi H, Qin H, Wanhainen K, et al. Preclinical development of a T cell ALL CAR demonstrates that differences in CAR membrane distribution may impact efficacy. Poster presented at the American Society of Hematology Meeting San Diego, CA 2016

Shalabi H, Shah NN, Fry TJ. Minimal Residual Disease Complete Remissions Following Anti-CD22 Chimeric Antigen Receptor (CAR) in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) Oral Presentation at the Center for Cancer Research Fellows and Young Investigators Colloquium Rockville, MD 2017

Shah NN, Highfill SL, **Shalabi H**, Yates B, et al. CD4/CD8 T-Cell Selection Enhances CD22 CAR-T Cell Transduction and in-Vivo CAR-T Expansion: Updated Results on Phase I Anti-CD22 CAR Dose Expansion Cohort. Oral presentation: To be presented at the American Society of Hematology Meeting Atlanta, GA 2017

Shah NN, **Shalabi H**, Yates B, Kane E, et al. Beyond Cytokine Storm: Optimizing Treatment Strategies to Target the Complex Interplay Between CAR Mediated Inflammatory Response, Disseminated Intravascular Coagulation and Macrophage Activation Syndrome. Poster presentation: To be presented at the American Society of Hematology Meeting Atlanta, GA 2017

Shalabi H, Yates B, Delbrook C, Yuan C, et al. Intensification of Lymphodepletion Enhances CAR Expansion After Re-Infusion. Poster presentation: To be presented at the American Society of Hematology Meeting Atlanta, GA 2017

Shalabi H, Yates B, Delbrook C, Fry TJ, Shah NN. Chimeric Antigen Receptor Induced Cytopenia Differs from Chemotherapy Induced Myelosuppression. American Society of Hematology Abstract Book Atlanta, GA 2017

Shalabi H, Delbrook C, Stetler-Stevenson M, et al. Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Can Render Patients with ALL into PCR-Negative Remission and Can be an Effective Bridge to Transplant (HCT). Oral presentation: To be presented at the American Society for Blood and Marrow Transplantation Meeting Salt Lake City UT 2018.

Honors:

2004-2006	National Psychology Honor Society- Psi Chi
2007-2010	National Osteopathic Honors Society-Sigma Sigma Phi
2010-2013	Magis Star Residency Leadership Award
2017	Outstanding Oral Presentation, NCI, Bethesda MD

2017	Young Investigator Travel Award, Center for Cancer Research, National Cancer Institute, Fellow and Young Investigator Colloquium
2017	Certificate of Excellence Award for Fellows > 2 years in research, Research Roundup, Pediatric Oncology Branch, NCI
2017	NIH Director's Award, Pediatric Hematologic Malignancies Translational Team
2017	Next Gen Award for Children's Cancer Research, Children's Cancer Foundation/Giant Food
2017	Best Abstracts Award, American Society for Blood and Marrow Transplantation Salt Lake City, UT 2018